References
- 1. SUNG H, FERLAY J, SIEGEL RL, LAVERSANNE M, SOERJOMATARAM I, JEMAL A., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin, 2021;71:209–249.
- 2. GROOT PMD, WU CC, CARTER BW, MUNDEN RF. The epidemiology of lung cancer. Translational lung cancer research, 2018;7(3): 220–233.
- 3. NATIONAL COMPREHENSIVE CANCER NETWORK. Non-Small Cell Lung Cancer, Version 4.2021-March 3, 2021.
- 4. AYOOLA A, BAROCHIA A, BELANI K, BELANI CP. Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation, 2012;30:433–446.
- 5. SCHWARTZ LH, LITIERE S, VRIES ED, FORD R, GWYTHER S, MANDREKAR S., et al. RECIST 1.1 – Update and Clarification: From the RECIST Committee. Eur J Cancer, 2016; 62: 132–137.
- 6. YOSHIDA T, YOH K, NIHO S, UMEMURA S, MATSUMOTO S, OHMATSU H., et al. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboringan EGFR mutation. Lung Cancer, 2015.
- 7. BARRON F, CARDONA AF, CORRALES L, RAMIREZ-TIRADO LA, CABALLE-PEREZ E, SANCHEZ G., et al. Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. J Thorac Dis, 2018;10(4):2166–2178.
- 8. GOMEZ XE, SOTO A, GOMEZ MA. Survival and prognostic factors in non-small cell lung cancer patients with mutation of the EGFR gene treated with tyrosine kinase inhibitors in a peruvian hospital. Am J Cancer Res, 2019;9(5):1009–1016.
- 9. KIM SY, MYUNG JK, KIM HR, NA II, KOH JS, BAEK HJ., et al. Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma. Tuberc Respir Dis, 2019;82:62–70.
- 10. IGAWA S, SASAKI J, OTANI S, ISHIHARA M, TAKAKURA A, KATAGIRI M., et al. Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. Oncology, 2015;89:275–280.
- 11. DOUILLARD JY, OSTOROS G, COBO M, CIULEANU T, MCCORMACK R, WEBSTER A., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. British Journal of Cancer, 2014;110:55–62.
- 12. ROTELLA V, FORNARO L, VASILE E, TIBALDI C, BOLDRINI L, CHELLA A., et al. EGFR and KRas mutations in women with lung adenocarcinoma: implications for treatment strategy definition. Journal of Experimental and Clinical Cancer Research, 2014;33:77
- 13. YU JY, YU SF, WANG SH, BAI H, ZHAO J, AN TT., et al. Clinical outcomes of EGFRTKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 2. Chinese Journal of Cancer, 2016;35:30.
- 14. OUYANG W, YU J, HUANG Z, CHEN G, LIU Y, LIAO Z., et al. Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Journal of Cancer, 2020; 11(8):2060–2067.
- 15. WHEATLEY-PRICE P, DING K, SEYMOUR L, CLARK GM, SHEPHERD FA. Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008;26(14):2350–2357.
- 16. ROZENSZTAJN N, RUPPERT AM, LAVOLE A, LEPRIEUR EG, DURUISSEAUX M, VIEIRA T., et al. Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. Cancer Medicine, 2014;3(1):61-69.
- 17. TSAI MJ, HUNG JY, LEE MH, KUO CY, TSAI YC, TSAI YM., et al. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors. Cancer, 2018; 10.
- 18. ZHANG P, NIE X, BIE Z, LI L. Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Medicine, 2018;97:9
- 19. HASEGAWA Y, ANDO M, MAEMONDO M, YAMAMOTO S, ISA SI, SAKA H., et al. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR)Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. The Oncologist, 2015;20:307–315.
- 20. TANIGUCHI Y, TAMIYA A, NAKAHAMA K, NAOKI Y, KANAZU M, OMACHI N., et al. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncology Letters, 2017;14:7589–7596.
- 21. HSU F, CALUWE AD, ANDERSON D, NICHOL A, TORIUMI T, HO C. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Curr Oncol, 2017 Aug;24(4):228–233.
- 22. XU C, YAO X, LI T, WANG J, AN B, WANG J., et al. Pretreatment neutrophil-tolymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer. Transl Cancer Res, 2020;9(4):2875–2883.
- 23. TANG M, GAO X, SUN H, TIAN S, DONG J, LIU Z., et al. Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis. Journal of Oncology, 2021.
- 24. PHAN TT, HO TT, NGUYEN HT, NGUYEN HT, TRAN TB, NGUYEN ST. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. International Journal of General Medicine, 2018;11:423–430.
- 25. URIBE-QUEROL E, ROSALES C. Neutrophils in Cancer: Two Sides of the Same Coin. Journal of Immunology Research, 2015;2015.
- 26. WON YW, HAN JY, LEE GK, PARK SY, LIM KY, YOON KA., et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol, 2011;64:947e952.
- 27. JIANG H, ZHU M, LI Y, LI Q. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. Mol Clin Oncol, 2019; 11(3): 301–308
- 28. MATSUO N, AZUMA K, SAKAI K, HATTORI S, KAWAHARA A, ISHII H., et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Scientific Report, 2016;6.